Pulmonary alveolar proteinosis - Is host defense awry? by Doerschuk, C.M.
n engl j med 356;6 www.nejm.org february 8, 2007
PERSPECTIVE
547
Pulmonary alveolar proteinosis is a rare disorder caused by 
abundant accumulation of sur-
factant-derived components in the 
lungs. The incidence is estimated 
to be 0.36 case per million pop-
ulation, and the prevalence, 3.70 
cases per million.1 About 500 cas-
es have been recorded in the lit-
erature.
The condition usually presents 
as progressive dyspnea and a min-
imally productive cough. There 
are elevated serum levels of prod-
ucts derived from pulmonary epi-
thelial cells, including cytokeratin 
19, the mucin KL-6, and surfac-
tant proteins A, B, and D. Pul-
monary-function testing reveals 
a restrictive pattern and a dis-
proportionate reduction in dif-
fusing capacity. Patients often have 
hypoxemia, and the partial pres-
sure of oxygen in the arteries is 
elevated as compared with that in 
the alveoli. The appearance of the 
lungs on high-resolution comput-
ed tomography is often a homo-
geneous ground-glass haze over-
laid by thickened interlobular 
septa forming geometric shapes 
— the “crazy paving” pattern.
Diagnosis usually requires lung 
biopsy. The characteristic patho-
logical feature is the filling of 
alveoli and distal bronchioles with 
surfactant-derived material that is 
granular, acidophilic, acellular, 
and amorphous; periodic acid–
Schiff staining is positive and 
diastase-resistant. The material 
consists of approximately 90% lip-
id (primarily phospholipids), 10% 
protein, and 1% carbohydrate and 
is usually sterile. Large foamy al-
veolar macrophages are present, 
and the alveolar structure is pre-
served until late in the course of 
disease. Mild interstitial lympho-
cytic infiltrates may be present.
Pulmonary alveolar proteino-
sis results either from decreased 
degradation of surfactant or from 
surfactant dysfunction and is 
classified as primary, secondary, 
or congenital. The congenital type 
has been attributed to one of two 
rare mutations: one causes a de-
ficiency of surfactant protein B, 
and the other causes abnormali-
ties in the β chain of the receptor 
for granulocyte–macrophage col-
ony-stimulating factor (GM-CSF). 
Secondary pulmonary alveolar pro-
teinosis occurs in patients with 
systemic inflammatory diseases 
or cancers (most commonly he-
matologic) or in association with 
inhalational exposure to silica, 
aluminum dust, titanium dioxide, 
or other material.
Primary pulmonary alveolar 
proteinosis accounts for nearly 
90% of cases and is virtually al-
ways attributable to neutralizing 
GM-CSF autoantibodies, which 
prevent the binding of GM-CSF 
to GM-CSF receptors on alveolar 
macrophages (see diagram). GM-
CSF–initiated signaling plays a 
unique, nonredundant role in al-
veolar macrophage function and 
pulmonary homeostasis.
The hypothesis that pulmonary 
alveolar proteinosis is due to in-
effective signaling by GM-CSF re-
ceptors was first put forward in 
1994, when Stanley et al.2 and 
Dranoff et al.3 simultaneously re-
ported on mice in which both al-
leles of the gene for GM-CSF are 
disabled. These GM-CSF−/− mice 
have striking pulmonary patho-
logic characteristics that closely 
resemble those of patients with 
pulmonary alveolar proteinosis, 
suggesting that the intracellular 
signaling initiated by the binding 
of GM-CSF to its receptor is criti-
cal to pulmonary surfactant ho-
meostasis. Signaling initiated by 
GM-CSF receptors is mediated 
through PU.1, a transcription fac-
tor modulating the expression of 
many genes that are important in 
the terminal differentiation of 
alveolar macrophages. Functions 
regulated by PU.1 include surfac-
tant degradation, expression of 
pathogen pattern-recognition re-
ceptors, toll-like–receptor signal-
ing, phagocytosis, and bacterial 
killing. Reconstitution of PU.1 in 
GM-CSF–deficient alveolar mac-
rophages restores most of these 
functions. GM-CSF signaling also 
enhances the function of peroxi-
some-proliferator–activated recep-
tor γ (PPARγ), another transcrip-
tion factor that regulates many 
cellular functions, including in-
tracellular lipid metabolism. These 
findings explain how inhibiting 
the binding of GM-CSF to its re-
ceptor causes decreased clearance 
of surfactant from the alveolar 
spaces. GM-CSF is required for 
the terminal differentiation and 
function of alveolar macrophages 
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but not for those of other tissue 
macrophages — which may ex-
plain why pulmonary alveolar 
proteinosis is primarily a lung 
disease.4
The discovery that nearly all 
patients with primary pulmonary 
alveolar proteinosis have high ti-
ters of GM-CSF antibodies has 
led to the development of new 
therapies based on granulocyte 
colony-stimulating factor (G-CSF) 
supplementation. Previously, ther-
apy consisted of whole-lung la-
vage, which results in numerous 
complications and does not ad-
dress the pathogenetic mecha-
nisms. Administration of exoge-
nous GM-CSF appears to help 
many patients, and its potential 
as a subcutaneous or aerosolized 
therapy is being evaluated.
Whether patients with pulmo-
nary alveolar proteinosis have de-
fects in host defense and innate 
immunity is not clear, nor is the 
effect of such defects. GM-CSF−/− 
mice clearly have a defect in pul-
monary defense against patho-
gens, as well as extrapulmonary 
abnormalities and a decreased 
susceptibility to experimentally 
induced autoimmune disorders. 
Patients with pulmonary alveo-
lar proteinosis do not have defi-
cient expression of GM-CSF, but 
they have neutralizing GM-CSF 
autoantibodies, which may ac-
count for differences between 
host defense defects in such pa-
tients and defects in mice. Al-
though secondary infections have 
been described in these patients, 
our understanding of host defense 
in this disorder is limited by its 
rarity, the variability of its out-
comes, and reporting biases. Pa-
tients may be at risk for second-
ary infections, but bacteria that 
commonly cause respiratory in-
fections are not often the inciting 
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Pathophysiology of Pulmonary Alveolar Proteinosis.
GM-CSF–initiated signaling (Panel A) plays unique, nonredundant roles in alveolar macrophage function and pulmonary homeo-
stasis, including terminal differentiation and survival of macrophages, intracellular lipid metabolism, surfactant catabolism and 
recycling, expression of pathogen receptors, and phagocytosis and killing. These functions are inhibited when neutralizing GM-CSF 
autoantibodies bind to GM-CSF (Panel B), block its binding to the α chain of the GM-CSF receptor, and prevent assembly of the 
GM-CSF–receptor complex. Thus, inhibition of GM-CSF binding to its receptor by autoantibodies results in decreased clearance of 
surfactant from the alveolar spaces, the hallmark of pulm nary alveolar proteinosis.
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agents.1 Opportunistic pathogens 
— most commonly nocardia, but 
occasionally cryptococcus, histo-
plasma, aspergillus, or Mycobac-
terium tuberculosis — have been 
reported in about 13% of pa-
tients,1 with systemic infection 
documented in some cases. In a 
review of 65 cases in which death 
was attributable to pulmonary al-
veolar proteinosis, respiratory 
failure was the apparent cause of 
death in 47 cases (72%), whereas 
uncontrolled infection was the 
cause in 12 (18%).1 These find-
ings suggest that clinically im-
portant lung infections occur in 
some patients and that systemic 
infections are less common.
Few researchers have investi-
gated whether GM-CSF autoanti-
bodies cause defects in cells, oth-
er than alveolar macrophages, that 
express GM-CSF receptors. In this 
issue of the Journal, Uchida et al. 
report on the effects of GM-CSF 
autoantibodies on neutrophil func-
tions (pages 567–579). Their ob-
servations show that neutrophils 
from patients with pulmonary 
alveolar proteinosis have defects 
in both basal and GM-CSF–
primed antimicrobial functions. 
In particular, the phagocytic in-
dex and phagocytic capacity of 
neutrophils isolated from these 
patients were approximately 90% 
and 30% lower, respectively, than 
those of neutrophils from healthy 
control subjects. The basal capac-
ity for adhesion to plastic, the 
oxidative burst in whole blood, 
and the killing of Staphylococcus 
aureus were also reduced. Fur-
thermore, GM-CSF priming in vi-
tro was impaired. Similar defects 
in basal neutrophil functions were 
observed in GM-CSF−/− mice, al-
though no defect in GM-CSF 
priming was observed. The de-
fect in affected human neutro-
phils was mimicked by treating 
blood from healthy control sub-
jects with GM-CSF autoantibod-
ies. Thus, neutrophils from pa-
tients with pulmonary alveolar 
proteinosis have functional de-
fects when tested in vitro.
How the signaling of GM-CSF 
through its receptor on neutro-
phils augments neutrophil func-
tion remains an important ques-
tion.5 PU.1 is apparently critical 
in GM-CSF–initiated signaling in 
alveolar macrophages but not in 
neutrophils, since Uchida et al. 
show that neutrophils from pa-
tients with pulmonary alveolar 
proteinosis do not have lower 
PU.1 expression than those from 
healthy control subjects. Fur-
thermore, defects in neutrophil 
function are apparent in vitro, 
but it is not clear how they con-
tribute to a defect in host de-
fense in vivo. Humans and mu-
tant mice with defects in innate 
immunity, including abnormal 
neutrophil function, often have 
increased blood levels of neutro-
phils, G-CSF, and cytokines; the 
failure to destroy pathogens leads 
to the persistence of pathogen-
induced stimuli. In contrast, in 
the study by Uchida et al., patients 
with pulmonary alveolar protein-
osis who had defective neutrophil 
function in vitro did not have 
increased neutrophil counts and 
serum G-CSF levels, suggesting 
that their host defense and innate 
immunity were sufficient for man-
aging daily exposures to common 
pathogens and commensal organ-
isms. Clinically apparent infec-
tions, especially with opportun-
istic microbes, do occur in some 
patients; microbes were identified 
at presentation in more than 
half the patients studied by Uchi-
da et al.
Whether host defense mecha-
nisms are able to compensate for 
defects in neutrophil and macro-
phage function until the environ-
ment delivers a particular patho-
gen or a large load of pathogens, 
or until a combined assault is 
made on the immune system, re-
mains to be elucidated. The ab-
sence of repeated infections, par-
ticularly in the lungs, is surprising, 
given the magnitude of the neu-
trophil defects seen in vitro; 
perhaps products of surfactant 
degradation have important an-
timicrobial effects. Clearly, the 
study by Uchida et al. raises im-
portant, provocative questions that 
beg to be pursued.
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